Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt015PMID 23406731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• Ultraviolet A and photosensitivity during vemurafenib therapy.

  2012cited by this paper
• RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Overcoming metastatic melanoma with BRAF inhibitors

  2011cited by this paper
• Vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

  2011cited by this paper
• Vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

  2009cited by this paper
• p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

  2009cited by this paper
• Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

  2008cited by this paper
• Sorafenib-induced eruptive melanocytic lesions.

  2008cited by this paper
• Autosomal-dominant calcium ATPase disorders.

  2006cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper

• BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.

  2026cites this paper
• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies

  2025cites this paper
• Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation

  2025cites this paper
• [Cutaneous cysts].

  2025cites this paper
• A Comprehensive Review of RAF Kinase: Advances in Inhibition Strategies for Drug Development

  2025cites this paper
• Erdheim-Chester disease: Comprehensive insights from genetic mutations to clinical manifestations and therapeutic advances.

  2025cites this paper
• Successful Treatment of BRAF-Mutated Metastatic Melanoma in an Advanced-Age Patient with Dabrafenib and Trametinib: A Case Report and Literature Review

  2025cites this paper
• Targeted treatment for craniopharyngioma

  2025cites this paper
• The evolving landscape of tissue‐agnostic therapies in precision oncology

  2024cites this paper
• Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma Patients—A Case Report

  2024cites this paper
• Types and severity of cutaneous toxicities to BRAF inhibitors are drug-specific and discrete: a single-center cohort study.

  2024cites this paper
• Successfully Nonsurgical Epidermoid Cyst Management with Recombinant Hydrolytic Enzymes: A Case Report

  2024cites this paper
• Sorafenib-induced bilateral oral hyperkeratosis

  2024cites this paper
• Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors

  2024cites this paper
• BRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis

  2024cites this paper
• Practical application of precision oncology in adult onset craniopharyngiomas

  2024cites this paper
• Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

  2023cites this paper
• Panniculitis does not predict clinical response in patients with advanced melanoma under targeted therapy

  2023cites this paper
• Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies

  2023influential citation
• The phenomenon of phototoxicity and long-term risks of commonly prescribed and structurally diverse drugs

  2023cites this paper
• Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors.

  2023cites this paper
• Pediatric low-grade glioma: State-of-the-art and ongoing challenges.

  2023cites this paper
• Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

  2023cites this paper
• Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib

  2022cites this paper
• Dermatological Aspects of Nursing Oncology: Meaningful Observations Ensuring Better Quality of Life

  2022cites this paper
• Dermoscopy to the Rescue

  2022cites this paper
• Reader Comment Regarding “Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review”

  2022cites this paper
• Anticancer treatments and photosensitivity

  2022cites this paper
• Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis

  2022cites this paper
• The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature

  2021cites this paper
• Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis

  2021cites this paper
• [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].

  2021cites this paper
• Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

  2021cites this paper
• Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies

  2021cites this paper
• Review BRAF inhibition and the spectrum of granulomatous reactions.

  2021cites this paper
• Erdheim-Chester Disease: a comprehensive review from the ophthalmologic perspective.

  2021cites this paper
• The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma

  2021cites this paper
• Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib

  2021cites this paper
• Skin Cyst: A Pathological Dead-End With a New Twist of Morphogenetic Potentials in Organoid Cultures

  2021cites this paper
• Dermatological Complications of Systemic Therapies for Melanoma

  2020cites this paper
• Dermatological Toxicities of Targeted Therapy

  2020cites this paper
• Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond

  2020cites this paper
• Pembrolizumab-induced lobular panniculitis in the setting of metastatic melanoma.

  2020cites this paper
• Cutaneous Reactions in Children Treated with MEK Inhibitors, BRAF Inhibitors, or Combination Therapy: A Multi-Center Study.

  2020cites this paper
• Oral mucositis: the hidden side of cancer therapy

  2020cites this paper
• A Recent Update on Histiocytic Disorder in Children: Focus on Diagnosis and Treatment

  2020cites this paper
• Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration

  2020cites this paper
• Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation

  2020cites this paper
• Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review

  2020cites this paper
• Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs

  2020cites this paper
• Photosensitivity and cancer immune‐targeted therapies

  2020cites this paper
• DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity

  2020cites this paper
• Practical Guide to Dermatology: The Henry Ford Manual

  2020cites this paper
• Eruptive Melanocytic Nevi: A Review

  2019cites this paper
• [Anti-TNF alpha-induced eruptive nevi: Three cases].

  2019cites this paper
• Darkening and eruptive nevi during treatment with erlotinib.

  2019cites this paper
• Vasculitis secundaria al uso de vemurafenib en una paciente con melanoma metastásico. Una complicación infrecuente de un inhibidor BRAF

  2019cites this paper
• Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency

  2019cites this paper
• Oral Mucosal Injury Caused by Targeted Cancer Therapies.

  2019cites this paper
• Common Cutaneous Side Effects of Anti-cancer Agents

  2019cites this paper
• Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.

  2019cites this paper
• Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study

  2019cites this paper
• Eruptive Nevi on the Palms and Soles with no Association with an Underlying Disease or Medications.

  2019cites this paper
• Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

  2019cites this paper
• Voetproblematiek bij een oncologisch behandeltraject

  2018cites this paper
• Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma

  2018cites this paper
• Étude rétrospective des effets indésirables cutanés du vemurafenib dans une cohorte européenne d’enfants traités pour histiocytose langerhansienne réfractaire

  2018influential citation
• Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib

  2018cites this paper
• Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy

  2018cites this paper
• Dermatologic Side Effects of Systemic Targeted Anticancer Therapy

  2018cites this paper
• RASopathic comedone‐like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH

  2018cites this paper
• Vemurafenib-induced plantar hyperkeratosis.

  2018cites this paper
• Cutaneous toxicities of new treatments for melanoma

  2018cites this paper
• Darier disease‐like hyperkeratotic papules and invasive squamous cell carcinoma in a patient with melanoma treated with dabrafenib

  2018cites this paper
• Interleukin‐17‐mediated manifestation of psoriasis and tinea

  2018cites this paper
• Transforming Growth Factor Beta (TGF-β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2018cites this paper
• Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines.

  2018cites this paper
• The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions

  2018cites this paper
• Mechanisms of resistance to BRAF and MeK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

  2018cites this paper
• Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

  2018cites this paper
• Eruptive melanocytic nevi associated with ponatinib

  2018cites this paper
• The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma

  2018cites this paper
• ERUPTIVE MELANOCYTIC NEVI

  2018cites this paper
• Systematic review and meta‐analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma

  2018cites this paper
• A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

  2017cites this paper
• Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

  2017cites this paper
• Eruptive Melanocytic Acral Nevi in the Setting of 6-mercaptopurine Therapy.

  2017cites this paper
• Delayed-onset vemurafenib-induced panniculitis

  2017cites this paper
• BRAF inhibitor‐associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management

  2017cites this paper
• The Many Faces of the Paradoxical Response to BRAF Inhibitors

  2017cites this paper
• Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from Trypanosoma brucei.

  2017cites this paper
• Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.

  2017cites this paper
• The Biology and Therapeutic Approach to BRAF -Mutant Cutaneous Melanoma

  2017cites this paper
• Cutaneous Drug Reactions in the Elderly

  2017cites this paper
• Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment

  2017cites this paper
• Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

  2017cites this paper
• Schattenseiten der Targeted Therapy

  2017cites this paper
• Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.

  2017cites this paper
• Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

  2017cites this paper